What DiaMedica Therapeutics Inc. does.

We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa), is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (rhKLK1) protein to be clinically studied in patients and has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of AIS. Kallikrein-1 (KLK1), extracted from human urine, is an established therapeutic modality in Asia for the treatment of AIS, and KLK1 produced from pig pancreas, is an established therapeutic modality for the treatment of cardio renal disease, including hypertension, in Asia. We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for PE, FGR and AIS. Longer term, we plan to develop DM300, our patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, as a potential therapy for severe acute pancreatitis.

Revenue and profit, by fiscal year.

More on DMAC.

• DiaMedica Therapeutics Inc. summary
• DiaMedica Therapeutics Inc. financial statements
• DiaMedica Therapeutics Inc. key metrics
• DiaMedica Therapeutics Inc. health scores and style box
• DiaMedica Therapeutics Inc. earnings
• DiaMedica Therapeutics Inc. dividends
• DiaMedica Therapeutics Inc. valuation
• DiaMedica Therapeutics Inc. ownership and insiders
• DiaMedica Therapeutics Inc. peers

Figures from DiaMedica Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.